New cocktail of drugs takes on pancreatic cancer
NCT ID NCT07131514
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of four drugs (HRS-4642, gemcitabine, albumin-bound paclitaxel, and adebrelimab) as treatment for pancreatic cancer before and after surgery. The goal is to see if this approach is safe and effective at shrinking tumors and improving survival. The study plans to enroll 30 adults with resectable or borderline resectable pancreatic cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-4642 combined with gemcitabine, albumin-bound paclitaxel, and adebrelimab
What this could lead to
If successful, this could lead to a more effective treatment approach for pancreatic cancer, potentially improving survival and reducing recurrence after surgery.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug combination may cause significant side effects, and it is not yet proven to work better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China